Kevin Deane
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 126 | 2026 | 1170 | 18.950 |
Why?
| | Autoantibodies | 69 | 2026 | 1497 | 7.860 |
Why?
| | Anti-Citrullinated Protein Antibodies | 31 | 2026 | 126 | 6.940 |
Why?
| | Rheumatoid Factor | 42 | 2026 | 175 | 5.540 |
Why?
| | Peptides, Cyclic | 32 | 2026 | 275 | 3.580 |
Why?
| | Antirheumatic Agents | 13 | 2026 | 303 | 3.240 |
Why?
| | Autoimmunity | 23 | 2025 | 925 | 3.090 |
Why?
| | Malaria | 3 | 2025 | 72 | 1.770 |
Why?
| | Rheumatic Diseases | 4 | 2022 | 95 | 1.630 |
Why?
| | Sputum | 5 | 2025 | 314 | 1.620 |
Why?
| | Methotrexate | 5 | 2025 | 239 | 1.500 |
Why?
| | Lung Diseases, Interstitial | 11 | 2025 | 663 | 1.320 |
Why?
| | Hydroxychloroquine | 3 | 2026 | 63 | 1.280 |
Why?
| | Humans | 164 | 2026 | 143821 | 1.220 |
Why?
| | Biomarkers | 32 | 2026 | 4248 | 1.180 |
Why?
| | Disease Progression | 21 | 2026 | 2871 | 1.150 |
Why?
| | Immunoglobulin A | 11 | 2023 | 218 | 1.110 |
Why?
| | Arthralgia | 4 | 2025 | 58 | 1.110 |
Why?
| | HIV Infections | 5 | 2023 | 3048 | 1.060 |
Why?
| | Autoimmune Diseases | 5 | 2024 | 464 | 1.050 |
Why?
| | Autoantigens | 8 | 2023 | 429 | 0.960 |
Why?
| | Social Determinants of Health | 2 | 2025 | 294 | 0.870 |
Why?
| | Inflammation | 11 | 2025 | 2893 | 0.860 |
Why?
| | Middle Aged | 77 | 2026 | 35630 | 0.860 |
Why?
| | Female | 101 | 2026 | 77570 | 0.860 |
Why?
| | Male | 88 | 2026 | 71569 | 0.860 |
Why?
| | Bronchial Diseases | 3 | 2013 | 38 | 0.840 |
Why?
| | Early Medical Intervention | 2 | 2014 | 61 | 0.830 |
Why?
| | Risk Factors | 36 | 2026 | 10623 | 0.820 |
Why?
| | Extracellular Traps | 3 | 2021 | 57 | 0.800 |
Why?
| | Genetic Predisposition to Disease | 16 | 2023 | 2407 | 0.790 |
Why?
| | Rheumatology | 7 | 2025 | 132 | 0.770 |
Why?
| | Mucous Membrane | 2 | 2024 | 128 | 0.740 |
Why?
| | Lung Diseases | 4 | 2022 | 794 | 0.720 |
Why?
| | Early Diagnosis | 8 | 2022 | 247 | 0.720 |
Why?
| | Adult | 62 | 2026 | 40129 | 0.710 |
Why?
| | Mosquito Vectors | 1 | 2022 | 28 | 0.710 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2023 | 230 | 0.700 |
Why?
| | Insecticides | 1 | 2022 | 42 | 0.700 |
Why?
| | Lupus Erythematosus, Systemic | 4 | 2022 | 240 | 0.700 |
Why?
| | Case-Control Studies | 19 | 2025 | 3614 | 0.690 |
Why?
| | Joints | 4 | 2015 | 108 | 0.680 |
Why?
| | Precision Medicine | 3 | 2020 | 450 | 0.670 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 21 | 0.660 |
Why?
| | Epitopes | 8 | 2023 | 490 | 0.640 |
Why?
| | Aged | 45 | 2026 | 25615 | 0.630 |
Why?
| | Qualitative Research | 6 | 2025 | 1626 | 0.600 |
Why?
| | Citrullination | 2 | 2020 | 13 | 0.600 |
Why?
| | Histones | 4 | 2023 | 655 | 0.590 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 856 | 0.580 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 243 | 0.580 |
Why?
| | Lung | 7 | 2020 | 4143 | 0.570 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2020 | 243 | 0.530 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 98 | 0.530 |
Why?
| | Immunoglobulin G | 11 | 2023 | 899 | 0.520 |
Why?
| | Transgender Persons | 1 | 2020 | 200 | 0.510 |
Why?
| | Pedigree | 2 | 2020 | 512 | 0.510 |
Why?
| | Citrulline | 2 | 2016 | 46 | 0.500 |
Why?
| | Focus Groups | 4 | 2025 | 573 | 0.500 |
Why?
| | Synovitis | 2 | 2023 | 33 | 0.490 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2015 | 51 | 0.490 |
Why?
| | Human Migration | 1 | 2016 | 25 | 0.480 |
Why?
| | Transients and Migrants | 1 | 2016 | 27 | 0.480 |
Why?
| | B-Lymphocytes | 4 | 2025 | 889 | 0.480 |
Why?
| | Rituximab | 3 | 2025 | 210 | 0.470 |
Why?
| | Arthritis | 2 | 2016 | 95 | 0.470 |
Why?
| | Synovial Membrane | 4 | 2025 | 123 | 0.460 |
Why?
| | Prospective Studies | 22 | 2025 | 7900 | 0.460 |
Why?
| | Immunoglobulin M | 7 | 2023 | 287 | 0.450 |
Why?
| | Th17 Cells | 3 | 2025 | 104 | 0.430 |
Why?
| | Abatacept | 2 | 2025 | 56 | 0.430 |
Why?
| | Cytokines | 10 | 2023 | 2093 | 0.420 |
Why?
| | Sexual Behavior | 2 | 2016 | 490 | 0.420 |
Why?
| | Antipsychotic Agents | 1 | 2016 | 185 | 0.420 |
Why?
| | Pneumonia | 1 | 2020 | 641 | 0.410 |
Why?
| | Family | 7 | 2021 | 692 | 0.400 |
Why?
| | Patient Acceptance of Health Care | 1 | 2020 | 872 | 0.400 |
Why?
| | Psychotic Disorders | 1 | 2016 | 170 | 0.400 |
Why?
| | Risk-Taking | 1 | 2016 | 333 | 0.390 |
Why?
| | Chemokines | 2 | 2012 | 224 | 0.390 |
Why?
| | Endothelium, Vascular | 4 | 2013 | 965 | 0.390 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2013 | 47 | 0.380 |
Why?
| | Risk Assessment | 9 | 2025 | 3556 | 0.380 |
Why?
| | Tanzania | 3 | 2021 | 60 | 0.370 |
Why?
| | Hazardous Substances | 1 | 2012 | 15 | 0.370 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 228 | 0.370 |
Why?
| | Observational Studies as Topic | 2 | 2024 | 127 | 0.370 |
Why?
| | Mass Screening | 4 | 2025 | 1325 | 0.350 |
Why?
| | Susac Syndrome | 1 | 2011 | 3 | 0.340 |
Why?
| | Fatty Acids, Omega-3 | 3 | 2017 | 142 | 0.340 |
Why?
| | Smoking | 9 | 2024 | 1556 | 0.330 |
Why?
| | Gene-Environment Interaction | 1 | 2012 | 179 | 0.330 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 83 | 0.320 |
Why?
| | Mucin-5B | 3 | 2025 | 228 | 0.320 |
Why?
| | Malondialdehyde | 2 | 2020 | 30 | 0.320 |
Why?
| | Acetaldehyde | 2 | 2020 | 17 | 0.320 |
Why?
| | Protein Processing, Post-Translational | 1 | 2013 | 477 | 0.320 |
Why?
| | Social Stigma | 2 | 2023 | 150 | 0.310 |
Why?
| | Health Fairs | 1 | 2009 | 10 | 0.310 |
Why?
| | Antibodies, Antinuclear | 5 | 2023 | 61 | 0.310 |
Why?
| | Research Design | 3 | 2024 | 1121 | 0.310 |
Why?
| | Emigration and Immigration | 1 | 2010 | 64 | 0.310 |
Why?
| | Incidence | 10 | 2026 | 2845 | 0.310 |
Why?
| | Postmenopause | 7 | 2023 | 390 | 0.310 |
Why?
| | Glucocorticoids | 3 | 2021 | 539 | 0.290 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2025 | 1223 | 0.290 |
Why?
| | Antibodies, Bacterial | 3 | 2023 | 147 | 0.280 |
Why?
| | Uganda | 2 | 2025 | 89 | 0.280 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1047 | 0.270 |
Why?
| | Cross-Sectional Studies | 10 | 2025 | 5761 | 0.260 |
Why?
| | Interviews as Topic | 3 | 2025 | 884 | 0.260 |
Why?
| | B-Cell Activating Factor | 2 | 2024 | 21 | 0.260 |
Why?
| | Health Behavior | 3 | 2018 | 794 | 0.260 |
Why?
| | Animals | 12 | 2025 | 38140 | 0.250 |
Why?
| | Chlamydia trachomatis | 2 | 2025 | 51 | 0.240 |
Why?
| | Antibody Formation | 4 | 2023 | 294 | 0.240 |
Why?
| | Immunophenotyping | 2 | 2025 | 327 | 0.240 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 24 | 0.230 |
Why?
| | Qa-SNARE Proteins | 1 | 2025 | 19 | 0.230 |
Why?
| | Developing Countries | 2 | 2025 | 313 | 0.230 |
Why?
| | Chlamydia Infections | 2 | 2025 | 82 | 0.230 |
Why?
| | Vasculitis | 1 | 2005 | 67 | 0.230 |
Why?
| | HLA-B27 Antigen | 1 | 2024 | 16 | 0.220 |
Why?
| | Arthritis, Psoriatic | 1 | 2024 | 15 | 0.220 |
Why?
| | Complement Factor H | 1 | 2025 | 79 | 0.210 |
Why?
| | Complement Activation | 2 | 2025 | 411 | 0.210 |
Why?
| | Longitudinal Studies | 5 | 2025 | 2948 | 0.210 |
Why?
| | Spondylarthritis | 1 | 2024 | 50 | 0.210 |
Why?
| | Prevalence | 5 | 2025 | 2819 | 0.200 |
Why?
| | Likelihood Functions | 1 | 2024 | 140 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2024 | 78 | 0.200 |
Why?
| | Polysaccharides | 2 | 2017 | 89 | 0.200 |
Why?
| | Risk | 3 | 2016 | 901 | 0.200 |
Why?
| | Clinical Decision-Making | 2 | 2024 | 345 | 0.200 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2024 | 135 | 0.200 |
Why?
| | C-Reactive Protein | 7 | 2025 | 419 | 0.200 |
Why?
| | London | 1 | 2023 | 45 | 0.200 |
Why?
| | Estrogens | 3 | 2017 | 377 | 0.200 |
Why?
| | Africa South of the Sahara | 1 | 2023 | 49 | 0.200 |
Why?
| | HLA-DR Antigens | 1 | 2024 | 219 | 0.190 |
Why?
| | Protein-Arginine Deiminases | 3 | 2021 | 16 | 0.190 |
Why?
| | Down-Regulation | 1 | 2025 | 641 | 0.190 |
Why?
| | Autophagy | 1 | 2025 | 288 | 0.190 |
Why?
| | Time Factors | 6 | 2019 | 7068 | 0.190 |
Why?
| | Mouth Mucosa | 3 | 2023 | 89 | 0.190 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 37 | 0.190 |
Why?
| | Young Adult | 10 | 2025 | 13914 | 0.190 |
Why?
| | Trichloroethylene | 1 | 2022 | 8 | 0.190 |
Why?
| | Periodontal Diseases | 1 | 2023 | 61 | 0.190 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 481 | 0.180 |
Why?
| | Patient Education as Topic | 3 | 2018 | 791 | 0.180 |
Why?
| | Insecticide-Treated Bednets | 1 | 2022 | 7 | 0.180 |
Why?
| | Gender Identity | 1 | 2023 | 124 | 0.180 |
Why?
| | Policy | 1 | 2023 | 147 | 0.180 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1133 | 0.180 |
Why?
| | Women's Health | 5 | 2017 | 311 | 0.180 |
Why?
| | Biological Products | 2 | 2022 | 252 | 0.180 |
Why?
| | Blood Platelets | 1 | 2025 | 396 | 0.170 |
Why?
| | Leukocytes, Mononuclear | 3 | 2024 | 580 | 0.170 |
Why?
| | Homosexuality, Male | 1 | 2023 | 215 | 0.170 |
Why?
| | Pulmonary Fibrosis | 1 | 2025 | 395 | 0.170 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2025 | 945 | 0.170 |
Why?
| | Sex Factors | 5 | 2020 | 2078 | 0.170 |
Why?
| | Organ Specificity | 2 | 2019 | 308 | 0.170 |
Why?
| | Double-Blind Method | 1 | 2026 | 2017 | 0.170 |
Why?
| | Lymphocyte Activation | 1 | 2025 | 1143 | 0.170 |
Why?
| | Housing | 1 | 2022 | 145 | 0.170 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2021 | 97 | 0.160 |
Why?
| | Neutrophil Activation | 1 | 2021 | 85 | 0.160 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2022 | 97 | 0.160 |
Why?
| | Sarcoidosis | 1 | 2022 | 159 | 0.160 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 9 | 0.160 |
Why?
| | Chemokine CXCL16 | 1 | 2020 | 4 | 0.160 |
Why?
| | Hemorrhage | 1 | 2005 | 799 | 0.160 |
Why?
| | Museums | 1 | 2000 | 11 | 0.160 |
Why?
| | Intestines | 2 | 2021 | 354 | 0.160 |
Why?
| | Sjogren's Syndrome | 1 | 2020 | 36 | 0.160 |
Why?
| | Cytomegalovirus Infections | 1 | 2022 | 205 | 0.160 |
Why?
| | Severity of Illness Index | 8 | 2022 | 2926 | 0.160 |
Why?
| | Muramidase | 1 | 2020 | 67 | 0.160 |
Why?
| | Public-Private Sector Partnerships | 1 | 2020 | 45 | 0.150 |
Why?
| | Complement System Proteins | 2 | 2022 | 315 | 0.150 |
Why?
| | Pandemics | 2 | 2025 | 1675 | 0.150 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 190 | 0.150 |
Why?
| | Art Therapy | 1 | 2000 | 21 | 0.150 |
Why?
| | T-Lymphocytes | 2 | 2025 | 2041 | 0.150 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2020 | 89 | 0.150 |
Why?
| | United Kingdom | 1 | 2020 | 332 | 0.150 |
Why?
| | Bacteriophages | 1 | 2021 | 111 | 0.150 |
Why?
| | Attitude | 1 | 2021 | 257 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2024 | 16754 | 0.150 |
Why?
| | Age Factors | 7 | 2020 | 3288 | 0.150 |
Why?
| | Nuclear Family | 1 | 2019 | 52 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2020 | 511 | 0.140 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 36 | 0.140 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 48 | 0.140 |
Why?
| | Gene Expression | 2 | 2022 | 1512 | 0.140 |
Why?
| | Arthritis, Experimental | 1 | 2020 | 143 | 0.140 |
Why?
| | Mitochondria | 2 | 2025 | 983 | 0.140 |
Why?
| | Dexamethasone | 1 | 2020 | 373 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 482 | 0.140 |
Why?
| | Socioeconomic Factors | 4 | 2025 | 1327 | 0.140 |
Why?
| | Occupational Exposure | 1 | 2022 | 352 | 0.140 |
Why?
| | Proteomics | 1 | 2025 | 1192 | 0.140 |
Why?
| | Vascular Stiffness | 2 | 2013 | 462 | 0.130 |
Why?
| | United States | 9 | 2025 | 15602 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 543 | 0.130 |
Why?
| | HLA-DR4 Antigen | 3 | 2007 | 75 | 0.130 |
Why?
| | Cohort Studies | 10 | 2022 | 5861 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2025 | 1078 | 0.130 |
Why?
| | Remission Induction | 2 | 2021 | 307 | 0.130 |
Why?
| | Galactose | 1 | 2017 | 33 | 0.130 |
Why?
| | Metabolome | 1 | 2020 | 383 | 0.130 |
Why?
| | Cellular Senescence | 1 | 2019 | 229 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 392 | 0.120 |
Why?
| | Coronary Disease | 2 | 2017 | 369 | 0.120 |
Why?
| | Glycosylation | 1 | 2017 | 173 | 0.120 |
Why?
| | Seroepidemiologic Studies | 3 | 2014 | 174 | 0.120 |
Why?
| | Military Personnel | 2 | 2021 | 694 | 0.120 |
Why?
| | Decision Making | 1 | 2024 | 967 | 0.120 |
Why?
| | Adiponectin | 1 | 2018 | 247 | 0.120 |
Why?
| | Sex Work | 1 | 2016 | 22 | 0.120 |
Why?
| | Plasma Cells | 1 | 2016 | 75 | 0.120 |
Why?
| | Hydrolases | 2 | 2021 | 55 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 227 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 5 | 2025 | 2782 | 0.120 |
Why?
| | Estradiol | 3 | 2017 | 538 | 0.120 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1984 | 0.110 |
Why?
| | Respiratory Function Tests | 3 | 2025 | 570 | 0.110 |
Why?
| | Diagnosis, Differential | 3 | 2013 | 1502 | 0.110 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2019 | 681 | 0.110 |
Why?
| | Mothers | 1 | 2021 | 769 | 0.110 |
Why?
| | Peptides | 1 | 2021 | 986 | 0.110 |
Why?
| | Diet | 2 | 2020 | 1266 | 0.110 |
Why?
| | Neutrophils | 1 | 2021 | 1144 | 0.110 |
Why?
| | Tertiary Prevention | 1 | 2014 | 3 | 0.110 |
Why?
| | Cardiovascular Diseases | 3 | 2017 | 2098 | 0.110 |
Why?
| | Vasodilation | 3 | 2013 | 522 | 0.110 |
Why?
| | Adaptation, Psychological | 1 | 2000 | 705 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 1032 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2020 | 831 | 0.100 |
Why?
| | Blood Pressure | 2 | 2017 | 1751 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 237 | 0.100 |
Why?
| | Respiratory Mucosa | 1 | 2016 | 326 | 0.100 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 166 | 0.100 |
Why?
| | Bacteroidaceae Infections | 1 | 2012 | 9 | 0.100 |
Why?
| | Family Health | 2 | 2013 | 193 | 0.100 |
Why?
| | Neoplasms | 2 | 2017 | 2902 | 0.100 |
Why?
| | Porphyromonas gingivalis | 1 | 2012 | 23 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 195 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2020 | 946 | 0.090 |
Why?
| | Vitamin D | 2 | 2022 | 402 | 0.090 |
Why?
| | Immune Tolerance | 1 | 2014 | 378 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 1915 | 0.090 |
Why?
| | Periodontitis | 1 | 2012 | 53 | 0.090 |
Why?
| | Communicable Disease Control | 2 | 2024 | 86 | 0.090 |
Why?
| | Health | 1 | 2012 | 83 | 0.090 |
Why?
| | Arthrography | 1 | 2011 | 18 | 0.090 |
Why?
| | Stress, Psychological | 1 | 2020 | 1147 | 0.090 |
Why?
| | Population Surveillance | 1 | 2015 | 491 | 0.090 |
Why?
| | Telomere Shortening | 2 | 2024 | 19 | 0.090 |
Why?
| | Pneumonia, Bacterial | 1 | 2013 | 113 | 0.090 |
Why?
| | Delayed Diagnosis | 1 | 2012 | 92 | 0.090 |
Why?
| | RNA, Messenger | 3 | 2025 | 2847 | 0.090 |
Why?
| | Disease Susceptibility | 3 | 2021 | 351 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2013 | 2097 | 0.090 |
Why?
| | Proportional Hazards Models | 3 | 2021 | 1305 | 0.080 |
Why?
| | Logistic Models | 5 | 2020 | 2095 | 0.080 |
Why?
| | Labor, Induced | 1 | 2011 | 36 | 0.080 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 98 | 0.080 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5316 | 0.080 |
Why?
| | Phenotype | 4 | 2023 | 3183 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2497 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2020 | 3392 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2011 | 267 | 0.080 |
Why?
| | Time-to-Treatment | 1 | 2012 | 235 | 0.080 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2011 | 128 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1402 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2012 | 332 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 431 | 0.080 |
Why?
| | Menopause | 1 | 2012 | 316 | 0.080 |
Why?
| | Colorado | 3 | 2020 | 4578 | 0.070 |
Why?
| | Air Pollution | 1 | 2013 | 326 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 101 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2013 | 333 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2021 | 11459 | 0.070 |
Why?
| | Interleukin-6 | 3 | 2021 | 791 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1968 | 0.070 |
Why?
| | Odds Ratio | 3 | 2018 | 1057 | 0.070 |
Why?
| | Prognosis | 3 | 2026 | 4210 | 0.070 |
Why?
| | Alleles | 3 | 2019 | 883 | 0.070 |
Why?
| | Aspirin | 1 | 2011 | 389 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 500 | 0.070 |
Why?
| | Colposcopy | 1 | 2007 | 18 | 0.070 |
Why?
| | Disease Outbreaks | 1 | 2010 | 423 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3073 | 0.060 |
Why?
| | Brachial Artery | 3 | 2013 | 207 | 0.060 |
Why?
| | Societies, Medical | 2 | 2021 | 865 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 29 | 0.060 |
Why?
| | Stroke | 1 | 2015 | 1219 | 0.060 |
Why?
| | Ultrasonography | 2 | 2025 | 766 | 0.060 |
Why?
| | Zimbabwe | 1 | 2025 | 67 | 0.060 |
Why?
| | Environment | 2 | 2019 | 306 | 0.060 |
Why?
| | Mice | 4 | 2025 | 18421 | 0.060 |
Why?
| | Switzerland | 1 | 2025 | 43 | 0.060 |
Why?
| | Premenopause | 2 | 2017 | 122 | 0.050 |
Why?
| | Capillaries | 1 | 2005 | 124 | 0.050 |
Why?
| | Radiography, Thoracic | 1 | 2005 | 176 | 0.050 |
Why?
| | Healthy Volunteers | 2 | 2017 | 218 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2005 | 227 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 56 | 0.050 |
Why?
| | Receptors, CXCR5 | 1 | 2024 | 27 | 0.050 |
Why?
| | Pregnancy | 2 | 2021 | 7154 | 0.050 |
Why?
| | Quarantine | 1 | 2024 | 31 | 0.050 |
Why?
| | Immunity, Mucosal | 2 | 2014 | 99 | 0.050 |
Why?
| | Aminosalicylic Acids | 1 | 2023 | 9 | 0.050 |
Why?
| | Interleukin-2 | 2 | 2016 | 447 | 0.050 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2023 | 26 | 0.050 |
Why?
| | Prevotella | 1 | 2023 | 26 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 390 | 0.050 |
Why?
| | Vimentin | 1 | 2023 | 54 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8130 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 399 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3834 | 0.050 |
Why?
| | Health Policy | 1 | 2025 | 390 | 0.050 |
Why?
| | Biopsy | 1 | 2005 | 1068 | 0.050 |
Why?
| | Employment | 1 | 2024 | 180 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2021 | 1508 | 0.040 |
Why?
| | Immunoglobulins | 2 | 2015 | 163 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2022 | 328 | 0.040 |
Why?
| | Carotid Arteries | 2 | 2013 | 203 | 0.040 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2021 | 35 | 0.040 |
Why?
| | Poverty | 1 | 2025 | 522 | 0.040 |
Why?
| | Body Mass Index | 2 | 2020 | 2439 | 0.040 |
Why?
| | Adolescent | 5 | 2025 | 22233 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2014 | 6004 | 0.040 |
Why?
| | Janus Kinase Inhibitors | 1 | 2021 | 28 | 0.040 |
Why?
| | Putrescine | 1 | 2020 | 3 | 0.040 |
Why?
| | Butyric Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Genetic Markers | 1 | 2022 | 338 | 0.040 |
Why?
| | Xenobiotics | 1 | 2021 | 33 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2022 | 173 | 0.040 |
Why?
| | Vitamins | 1 | 2022 | 177 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2005 | 843 | 0.040 |
Why?
| | Spermidine | 1 | 2020 | 18 | 0.040 |
Why?
| | Caprylates | 1 | 2020 | 27 | 0.040 |
Why?
| | Urban Population | 1 | 2024 | 485 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 86 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 285 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.040 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 76 | 0.040 |
Why?
| | Europe | 1 | 2021 | 410 | 0.040 |
Why?
| | Chemokine CXCL13 | 1 | 2020 | 15 | 0.040 |
Why?
| | Microbiota | 2 | 2021 | 781 | 0.040 |
Why?
| | Carnitine | 1 | 2020 | 87 | 0.040 |
Why?
| | Synovial Fluid | 1 | 2020 | 67 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2020 | 38 | 0.040 |
Why?
| | Survival Analysis | 2 | 2017 | 1358 | 0.040 |
Why?
| | Acute-Phase Proteins | 1 | 2020 | 67 | 0.040 |
Why?
| | Chemokine CXCL10 | 1 | 2020 | 40 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2021 | 273 | 0.040 |
Why?
| | Child Health | 1 | 2021 | 154 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2024 | 1192 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 690 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2020 | 376 | 0.040 |
Why?
| | Interleukin-1alpha | 1 | 2020 | 57 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 163 | 0.040 |
Why?
| | Ontario | 1 | 2000 | 94 | 0.040 |
Why?
| | Antibody Specificity | 1 | 2020 | 185 | 0.040 |
Why?
| | Interinstitutional Relations | 1 | 2000 | 52 | 0.040 |
Why?
| | Anxiety | 1 | 2007 | 1100 | 0.040 |
Why?
| | Baltimore | 1 | 2019 | 67 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4553 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 197 | 0.040 |
Why?
| | Tryptophan | 1 | 2020 | 180 | 0.040 |
Why?
| | Endotoxins | 1 | 2020 | 214 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 480 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2021 | 396 | 0.040 |
Why?
| | Rural Population | 1 | 2024 | 638 | 0.040 |
Why?
| | Genotype | 2 | 2018 | 1837 | 0.040 |
Why?
| | Interferons | 1 | 2020 | 193 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 726 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2018 | 19 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 252 | 0.030 |
Why?
| | Dysbiosis | 1 | 2020 | 186 | 0.030 |
Why?
| | Forecasting | 1 | 2020 | 388 | 0.030 |
Why?
| | Nurses | 1 | 2020 | 179 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3120 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 645 | 0.030 |
Why?
| | Gene Frequency | 1 | 2019 | 483 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2022 | 684 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 322 | 0.030 |
Why?
| | Genetic Testing | 1 | 2020 | 475 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2019 | 2167 | 0.030 |
Why?
| | Child | 4 | 2025 | 22440 | 0.030 |
Why?
| | Goserelin | 1 | 2017 | 8 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 499 | 0.030 |
Why?
| | Fertility Agents, Female | 1 | 2017 | 21 | 0.030 |
Why?
| | Raloxifene Hydrochloride | 1 | 2017 | 15 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2024 | 1327 | 0.030 |
Why?
| | Leuprolide | 1 | 2017 | 21 | 0.030 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2017 | 36 | 0.030 |
Why?
| | Genes, Immunoglobulin Light Chain | 1 | 2016 | 4 | 0.030 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.030 |
Why?
| | Phosphofructokinase-2 | 1 | 2016 | 16 | 0.030 |
Why?
| | Amino Acids | 1 | 2021 | 519 | 0.030 |
Why?
| | Decision Support Techniques | 1 | 2021 | 446 | 0.030 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2017 | 52 | 0.030 |
Why?
| | Phylogeny | 1 | 2021 | 1011 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.030 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 76 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 888 | 0.030 |
Why?
| | Protective Factors | 1 | 2016 | 102 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 750 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 680 | 0.030 |
Why?
| | Androgens | 1 | 2017 | 187 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2000 | 700 | 0.030 |
Why?
| | Health Education | 1 | 2018 | 358 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2016 | 130 | 0.030 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2017 | 212 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1522 | 0.030 |
Why?
| | Leukocyte Count | 1 | 2015 | 317 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2015 | 93 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1047 | 0.030 |
Why?
| | Child, Preschool | 2 | 2025 | 11630 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1255 | 0.030 |
Why?
| | Etanercept | 1 | 2013 | 60 | 0.030 |
Why?
| | HLA-DRB1 Chains | 1 | 2014 | 111 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 828 | 0.020 |
Why?
| | Motivation | 1 | 2018 | 607 | 0.020 |
Why?
| | Pneumocystis carinii | 1 | 2013 | 12 | 0.020 |
Why?
| | Geographic Information Systems | 1 | 2013 | 47 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 559 | 0.020 |
Why?
| | Testosterone | 1 | 2017 | 426 | 0.020 |
Why?
| | Oral Health | 1 | 2014 | 139 | 0.020 |
Why?
| | Interleukin-9 | 1 | 2012 | 13 | 0.020 |
Why?
| | Cell Membrane | 1 | 2016 | 709 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1638 | 0.020 |
Why?
| | Communication | 1 | 2018 | 960 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 306 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 576 | 0.020 |
Why?
| | Life Style | 1 | 2014 | 485 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 152 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2014 | 256 | 0.020 |
Why?
| | Connective Tissue Diseases | 1 | 2012 | 85 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 1057 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4106 | 0.020 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 342 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2013 | 377 | 0.020 |
Why?
| | Erythrocytes | 1 | 2016 | 757 | 0.020 |
Why?
| | Particulate Matter | 1 | 2013 | 342 | 0.020 |
Why?
| | Internet | 1 | 2014 | 699 | 0.020 |
Why?
| | Overweight | 1 | 2014 | 598 | 0.020 |
Why?
| | Exercise | 1 | 2021 | 2196 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 715 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2012 | 791 | 0.020 |
Why?
| | Self Report | 1 | 2013 | 865 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2620 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 121 | 0.020 |
Why?
| | Hypertension | 1 | 2015 | 1239 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2015 | 1088 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1843 | 0.020 |
Why?
| | Veterans | 1 | 2018 | 1586 | 0.010 |
Why?
| | Tobacco Smoke Pollution | 1 | 2007 | 236 | 0.010 |
Why?
| | Siblings | 1 | 2005 | 196 | 0.010 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 275 | 0.010 |
Why?
| | Pain | 1 | 2007 | 776 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2007 | 1688 | 0.010 |
Why?
| | Arthritis, Infectious | 1 | 1994 | 72 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2006 | 3838 | 0.000 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|